Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

Study summary

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedphlebotomy

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 22, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Stanford University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Stanford University
Interventions being studied: Procedure: phlebotomy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Inclusion Criteria:Inclusion Criteria (Cases): 1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC 2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection 3. ability to sign informed consent 4. at least 18 years of age Inclusion Criteria (Controls): 1. no known prior or active malignancy 2. ability to sign informed consent 3. at least 18 years of age

Reasons someone may not be able to joinExclusion criteria

1. history of any other cancer other than non-melanoma skin cancer within the last 5 years

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Stanford University School of MedicineStanford, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 22, 2022. Always confirm current availability with the study team.

View original record ↗